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Essentials
• Whether excess body weight influences recurrent venous thrombosis (VT) risk is uncertain.
• We included 3889 VT patients, classified into body mass index (BMI) strata to estimate recurrent VT risk.
• No evidence of an increased risk for excess body weight was found.
• Measuring BMI is not a good tool to identify patients at high risk of VT recurrence.
Summary. Background: Studies on the risk of recurrent venous thrombosis in patients with excess body weight have yielded conflicting results. Objective: To estimate whether excess body weight increases the risk of recurrent venous thrombosis. Patients/Methods: We included 3889 patients, followed after a first venous thrombosis for a median of 5.6 years. Body mass index (BMI) was calculated as weight in kilograms/height in meters squared, and classified according to three a priori-defined categories (normal weight, overweight, and obesity), as well as by percentiles. Crude incidence rates with 95% confidence intervals (CIs) of recurrent venous thrombosis were estimated as the number of events over the accumulated follow-up time in each BMI category. Cox regression models were used to compare groups, adjusted for age and sex. Results: The incidence rate of recurrent venous thrombosis was 3.3 per 100 patient-years. Adjusted hazard ratios of recurrent venous thrombosis in overweight or obese patients in comparison with patients with normal weight were 1.05 (95% CI 0.88-1.27) and 0.94 (95% CI 0.74-1.19), respectively. Stratification by BMI percentile categories yielded similar results. The association between BMI and recurrent venous thrombosis was also absent after stratification by sex, (although a small effect for overweight, but not for obese women, was found), or into those with a first provoked or unprovoked event, or deep vein thrombosis and pulmonary embolism. Conclusions: We found no evidence
Introduction
Venous thrombosis (VT), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is characterized by a high recurrence risk of 30-50% in 10 years [1] [2] [3] , in which transient risk factors (e.g. surgery), persistent risk factors (e.g. chronic comorbidity) or unknown risk factors (i.e. unprovoked risk factors) have important prognostic and treatment implications [4] . For these reasons, the identification of risk factors for recurrence is of great importance. Excess body weight is a major and growing health problem [5] , and is consistently associated with a two-fold to three-fold increased risk of a first VT in obese individuals (body mass index [BMI] of ≥ 30 kg m À2 ) as compared with normal-weight individuals (BMI of < 25 kg m À2 ) [6, 7] . The association between obesity and recurrent VT has been less frequently studied. In a cohort study from Austria, obese individuals had a 1.6-fold (95% confidence interval [CI] 1.1-2.4) higher risk of recurrence than those with normal weight [8] . In another study, a 10 kg m À2 increase in BMI was associated with a
As measuring height and weight is simple, BMI may be attractive for use as a prediction tool. However, excess body weight has not been associated with recurrent VT in other population-based studies [10, 11] . We investigated, in the Multiple Environmental and Genetic Assessment (MEGA) follow-up study, whether excess body weight increases the risk of recurrent VT classified by sex, type of first event, and first (un)provoked event.
Materials and methods

Study design
The study included patients who had a first episode of VT, and participated in the MEGA case-control study [12] . In short, between March 1999 and September 2004, 4956 patients aged 18-70 years, with a first diagnosis of DVT or PE, were asked to participate, shortly after they had attended six anticoagulation clinics in the Netherlands. Of 4956 eligible patients, 225 did not consent to be followed for recurrence, leaving 4731 patients. Between 2007 and 2009, the vital status of all of these participants was acquired from the central Dutch population register, as has been described previously [12] . For the patients who had died, a cause of death form (encoded according to the International Classification of Diseases ICD-10-CM) was obtained. The study was approved by the Medical Ethics Committee of the Leiden University Medical Center.
Inclusion/exclusion criteria
Of the 4731 patients included in the MEGA follow-up study [13] , we could analyse data from 3889 patients for whom BMI data, obtained at the time of study entry, were available. Patients with known cancer at baseline were excluded (n = 426), as cancer is a risk factor for recurrent VT (even when patients are anticoagulated) [14] , and may affect body weight.
Exposure classification
BMI was calculated as weight (kg)/height squared (m 2 ), and was classified according to three a priori-defined categories (in kg m À2 ), i.e. normal weight (< 25), overweight (< 30 and ≥ 25), and obese (> 30), and in percentiles according to the distribution in the controls from the MEGA study (< 10th, 10th-25th, 25th-75th [reference category], 75th-90th, and > 90th). Both height and weight were self-reported by the patients.
Outcome classification
Questionnaires concerning recurrent VT were sent by mail to all consenting patients between June 2008 and July 2009. When questionnaires were not returned, information was sought by telephone interview. During the same period, information about recurrent thrombotic events was retrieved from the anticoagulation clinics where patients were initially included for their first VT event. If they had moved, information was acquired from the clinic nearest to their new address. Deaths attributable to recurrent VT were counted as fatal recurrent events. For any suspected recurrent event, discharge letters were obtained from patients' hospitals. A decision rule regarding certainty of diagnosis was made on the basis of hospital discharge letters, the information from the anticoagulation clinics, questionnaires filled in by the patients, and causes of death [15] . According to these data, recurrent events were classified as certain and uncertain. In short, recurrent events were considered to be certain when a discharge letter stated a diagnosis of a recurrent event based on clinical and radiologic data, or both the anticoagulation clinic and the patient reported a recurrent event that was at a clearly different location from the first event, or occurred > 1 year after the first event, or, in the case of a registered death resulting from a recurrent event, at least 6 months after the first event. For our main analyses, we included certain recurrences as outcome events only.
Statistical analysis
Follow-up started at the moment of discontinuation of anticoagulant treatment. The end of follow-up was defined as the date of a recurrent thrombosis, date of death, date of emigration, or date of filling in the short questionnaire, whichever came first. If patients had not responded to the questionnaire or telephone interview, they were censored from the last date when we knew them to be recurrence-free (i.e. the last visit to the anticoagulation clinic, or the last moment when the patient was known to be recurrence-free according to information from the MEGA case-control study). Patients with uncertain recurrence were censored at the time when this event took place. In a sensitivity analysis, the follow-up time was started at the moment of VT onset. Crude incidence rates with 95% CIs of recurrent VT were calculated as number of events over the accumulated follow-up time in each BMI exposure category. Cox proportional hazard regression models were used to assess risk among groups. Hazard ratios (HRs) were adjusted for age and sex. We performed additional analyses by sex, by the type of first event (DVT or PE AE DVT), and for those with a first unprovoked or provoked event. To quantify potential misclassification of outcomes, we performed a sensitivity analysis for overall recurrent VT in which certain and uncertain recurrent events were both considered as recurrent events.
Results and discussion
A total of 3889 patients with a first VT were included in this study, of whom 1473 had a BMI of ≤ 25 kg m Table 1 .
During follow-up, 569 certain recurrent events and 119 uncertain recurrent events occurred, with an incidence rate of 3.2 per 100 patient-years for certain recurrences.
As compared with the normal-weight group, HRs, adjusted for age and sex, were 1.05 (95% CI 0.88-1.27) in the overweight and 0.94 (95% CI 0.74-1.19) in the obese group (Table 2) . In an analysis with BMI as a continuous variable, the adjusted HR was 1.01 (95% CI 0.99-1.03) per 1 unit increase in BMI. Sensitivity analyses yielded similar results, e.g. when uncertain and certain recurrent events were included as a combined outcome (Table 3) percentile group, all with the 25th-75th percentile group as reference category. Analyses in which we stratified by first unprovoked or first provoked event, by type of initial presentation (DVT or PE with or without DVT) and by sex also did not show an association across BMI categories and recurrent VT, except for overweight women (Table 4) .
In this large cohort study of patients with VT, we did not observe an increased risk of recurrent VT in overweight or obese patients. As overweight/obesity is consistently associated with the risk of a first episode of VT, our null findings may come as a surprise. However, it is not rare for factors that are established determinants for a first episode to not be associated with the risk of recurrence, as is also the case for thrombophilia and age. An explanation for this phenomenon is not the topic of this article, but can be found elsewhere [16] . The current results conflict with those of a longitudinal study (n = 1107) that found a 1.3-1.9-fold increased risk of recurrent VT in overweight individuals [8] . This could be attributable to a difference in inclusion criteria, because, in that study, 66% of consecutive patients with VT were excluded, whereas we only excluded patients with known malignancy (9%). In another population-based cohort study (n = 1719), the risk of recurrence was increased by 24% per 10 kg m À2 increase in BMI level [9] . However, when uncertain recurrent events were excluded from the analyses in that study, the risk of a recurrent event was closer to unity. Our results are in line with those of the FARIVE study [9] (n = 583), in which obesity was a risk factor for recurrent VT in women, but not in men (relative risk of 2.8 [95% CI 1.3-6.0] versus relative risk of 0.9 [95% CI 0.4-2.5], respectively). Other studies were too small to yield reliable results [11] . In the present large (n = 3889) cohort study, we followed patients for a long period of time (median of 5.6 years), and recurrent events were objectively confirmed and strictly classified [15] .
Because of the large sample size, several subgroup and sensitivity analyses could be performed. Detailed and precise risk estimates all pointed towards the absence of an association between overweight/obesity and recurrent VT, except for overweight women. As this is the largest study to date on this question, we consider it unlikely that our results are attributable to a type II error (i.e. failing to detect an effect because of small numbers). Our study has some limitations. First, excess body weight was assessed by use of the BMI, which is a good estimate of body fat but not of fat distribution. Previous data have shown that waist circumference is a preferable anthropometric measure of obesity to identify subjects at risk and to predict the risk of VT [17] . These indicators of fat distribution were not recorded in our study. Second, BMI was determined at the time of study entry only, and the effect of weight change throughout the follow-up period could therefore not be evaluated. Third, height and weight were self-reported. In general, underweight persons tend to over-report their body weight, whereas overweight persons tend to under-report their body weight, leading to BMI levels that will be lower than the actual BMIs [18] . Although these three limitations may all have led to underestimated associations, our results do show that self-reported BMI at the time of a first VT is not likely to be a useful predictor for recurrent VT. Moreover, the results solidly pointed to the absence of any association. Another limitation concerns the outcome classification, which was based on hospital discharge letters, the information from the anticoagulation clinic, questionnaires filled in by the patients, and causes of death [15] . Much information from radiologic and laboratory findings at the time of recurrence could be retrieved, but discharge letters often lacked precise information on DVT status obtained with both ultrasound and D-dimer © 2017 International Society on Thrombosis and Haemostasis testing when anticoagulant therapy was withdrawn. However, it is unlikely that any misclassification, which would be minor, because outcomes were strictly classified [15] , can explain our null results. A final limitation is that we did not have full information available for all patients, as some of them had not reported their BMI (9%). In summary, we have assessed the role of BMI in the risk of recurrent VT in a large unselected cohort of patients with a first VT, and found no evidence of an association. Measuring BMI is therefore not a useful tool for identifying patients at high risk of recurrent VT. BMI, body mass index; CI, confidence interval; DVT, deep vein thrombosis; PE, pulmonary embolism; py, patient-years.
*Adjusted for age and sex, where applicable.
